Versanis Presents Data Showing Bimagrumab Treatment Leads to Substantial Fat Mass Loss Associated with Lean Mass Gain in Diabetic and Non-Diabetic Patients | Antibody

Versanis Presents Data Showing Bimagrumab Treatment Results in Substantial Fat Mass Loss Associated with Lean Mass Gain in Diabetic and Non-Diabetic Patients

Presentation at ENDO 2022 shows similar beneficial improvement in body composition regardless of metabolic impairment

Phase 2b obesity study of bimagrumab monotherapy and co-administration with incretin therapy to begin later this year

NEW YORK, NY, USA I June 11, 2022 I Versanis Bio (“Versanis”), a clinical-stage company developing novel therapies for cardiometabolic diseases, will share analysis of Phase 2 data from prior studies of lead active bimagrumab at ENDO 2022, to be held virtually and in Atlanta June 11-14, 2022.

Dr. Lloyd Klickstein, Scientific Director of Versanis, will present the data during ENDO’s Rapid Fire Poster Session on Monday, June 13, from 12:30 p.m. to 1:30 p.m. EDT in Poster Pod 3, ENDOExpo Hall. The presentation is titled “Dramatic loss of fat mass caused by bimagrumab is similar in diabetic and non-diabetic patients”. The results of the analysis underscore the robust activity of bimagrumab in stimulating fat loss in diabetic and non-diabetic individuals, while simultaneously increasing lean body mass.

Bimagrumab is a first-in-class activin receptor type II monoclonal antibody previously evaluated in various muscle wasting indications for its effects on muscle anabolism. This pooled analysis is based on five previously completed Phase 2 studies with data from a total of 569 non-diabetic patients, 41% of whom were overweight or obese.

After just 24 weeks of intravenous bimagrumab treatment, the group receiving the highest dose lost 14.6% of their total body fat mass, while the placebo group showed a 2.4% increase in fat mass. This change in fat mass is similar to what was observed in a prospective study of 75 overweight and obese type 2 diabetic patients, where at week 24 fat mass loss was 16.5% in the bimagrumab group versus an increase of 0.8% in the placebo group. In this study, at week 48, fat mass in the bimagrumab group had decreased by 20.5%, while lean mass had increased by 3.6%, with no change in any parameter in the placebo group.

“This analysis further underscores the potential of bimagrumab to transform the lives of obese patients by enabling substantial fat loss with the added unique characteristic of increasing muscle mass, resulting in a significant improvement in body composition,” Klickstein said. “Furthermore, unlike other existing obesity treatments, bimagrumab demonstrates similar activity in diabetic and non-diabetic patient populations.”

Bimagrumab will enter a phase 2b study later this year in non-diabetic obese patients to assess its safety and efficacy both as monotherapy and when co-administered with incretin agonist therapy.

“While incretin therapies have been shown to be effective in weight loss, this comes at the expense of significant lean mass loss,” Klickstein said. “We believe co-administration of bimagrumab may prevent this adverse effect while amplifying overall fat loss.”

The goal of the combined Phase 2b study will be to demonstrate bimagrumab’s potential to become a new treatment option that helps obese patients lose substantial fat mass without compromising muscle mass or function.

About bimagrumab

Bimagrumab is a first-in-class fully human IgG1/λ monoclonal antibody directed against activin type II receptors that blocks the binding of ligands including myostatin, activins and GDF11. Bimagrumab decreases body fat, particularly abdominal visceral fat, while increasing muscle mass. Since initial development, bimagrumab has been administered to over 1,000 patients in more than 20 clinical studies. It is now being touted as a new treatment for obese patients, with additional directions to follow.

About Versanis

Versanis is a privately held, clinical-stage biopharmaceutical company transforming the life experience of people with cardiometabolic disease. The Company’s lead asset, bimagrumab, is in a Phase 2b study in obesity, with the goal of helping obese adults achieve and maintain both substantial fat loss and a healthy body composition. For more information, please visit

THE SOURCE: Versanis Bio

Comments are closed.